

## Table of Contents

Contents	I-VI
List of Figures	VII-XI
List of Tables	XII-XIII
List of abbreviations	XIV
<b>Chapter I Introduction &amp; Research Envisaged</b>	<b>1-71</b>
1.0. Introduction.....	1
1.1. Major factors influencing bioavailability of drugs .....	2
1.2. Strategies to improve bioavailability of drugs .....	4
1.2.1. Lipid based strategies.....	7
1.2.1.1. Lipid solutions and suspensions.....	7
1.2.1.2. Micro emulsions.....	8
1.2.1.3. Self-emulsifying drug delivery system (SEDDS).....	8
1.2.1.4. Self-microemulsifying drug delivery system (SMEDDS).....	9
1.2.1.5. Self-double emulsifying drug delivery system (SDEDDES).....	9
1.2.1.6. Solid-lipid nanoparticle (SLN) .....	10
1.2.1.7. Nanostructured lipid carriers.....	11
1.2.1.8. Lipid–drug conjugates (LDC).....	11
1.2.1.9. Nano emulsions.....	12
1.2.2. Intestinal transport improvement by drug nano carriers .....	13
1.2.2.1. Mucoadhesive nanoparticles .....	13
1.2.2.2. Permeation enhancer nanoparticles.....	13
1.2.2.3. Coated nanoparticles .....	14
1.2.2.4. Mucolytic nanoparticles.....	15
1.2.3. Different dosage form designing.....	15
1.2.3.1. Gastro retentive systems for the enhancement of site-specific absorption .....	15
1.2.3.2. Spray freeze drying .....	16
1.2.3.3. Chitosan derivatives .....	16
1.2.4. Chemical derivatization of Moiety .....	17
1.2.4.1. Prodrug.....	17

1.2.5. Utilization of chemicals .....	17
1.2.5.1. Bile salts .....	17
1.2.5.2. Saponins .....	18
1.2.5.3. Straight chain fatty acids .....	18
1.2.5.4. Natural bioenhancers.....	19
1.3. Gastrointestinal permeability and metabolism a major concern .....	19
1.4. Drug Metabolizing Enzymes (DMEs) .....	21
1.5. Efflux Drug Transports (EDTs).....	22
1.6. Tactics used to inhibit EDTs and DMEs.....	25
1.6.1. Synthetic approaches .....	26
1.6.1.1. Small molecule inhibitors [SMIs].....	26
1.6.2. Novel drug delivery system (NDDS) and synthetic excipients .....	27
1.6.3. Natural bioenhancers .....	30
1.6.3.1. Mechanism of Action.....	32
1.7. <i>In vitro</i> models for prediction of intestinal absorption .....	44
1.7.1. Parallel artificial membrane permeability assay (PAMPA).....	45
1.7.2. Caco-2 Cells .....	46
1.7.3. HT-29 and HT-29/Caco-2 Co-culture.....	46
1.7.4. Madin-Darby canine kidney (MDCK Cells).....	47
1.7.5. 2/4/A1 cell line.....	47
1.7.6. T-84.....	48
1.7.7. Lewis lung carcinoma-porcine kidney cells (LLC-PK1) .....	48
References.....	49

**Chapter II Plan of work** **72**

2.1. Aims and Objectives .....	72
--------------------------------	----

**Chapter III Drug and Bioenhancers profile** **73-87**

3.0. Bioenhancers Profile.....	73
3.0.1. Quercetin.....	73
3.0.1.1. Role of Quercetin as bioenhancer .....	74

3.0.2. Silibinin.....	75
3.0.2.1. Role of Silibinin as bioenhancer .....	75
3.0.3. Luteolin.....	77
3.0.3.1. Role of Luteolin as bioenhancer: .....	78
3.1. Drug Profile .....	79
3.1.1. Acyclovir.....	79
3.1.1.1. Mechanism of Action.....	80
3.1.1.2. Pharmacokinetic profile/Dispositions in the body.....	81
3.1.2. Saquinavir.....	82
3.1.2.1. Mechanism of action.....	83
3.1.2.2. Pharmacokinetic profile/Disposition in the Body .....	84
References.....	85

**Chapter IV Oral uptake enhancement of Acyclovir 88-167**

4.0. Introduction.....	88
4.1. Material and Methods .....	90
4.1.1. Materials and reagents .....	90
4.1.2. Analytical and Bio-analytical Method development and Validation.....	90
4.1.2.1. Zero order UV Spectroscopy method .....	90
4.1.2.2. LC-MS Method for estimation of ACV in Cell lines and plasma samples .....	98
4.1.3. Preparation of Physical Mixture of acyclovir and bioenhancers .....	105
4.1.3.1 Compatibility studies of binary system .....	105
4.1.4. <i>Ex-vivo</i> permeation studies .....	106
4.1.5. Cellular Uptake and Transport of ACV across the Caco-2 cell monolayers .....	108
4.1.5.1. Material .....	109
4.1.5.2. Cell Culture Protocol .....	109
4.1.6. <i>In vivo</i> pharmacokinetic study in rabbits .....	113
4.1.6.1. Animal preparation for <i>In-vivo</i> studies .....	113
4.1.6.2. Dosing.....	114
4.1.6.3. Analysis of plasma samples .....	114
4.1.6.4. Pharmacokinetic and Statistical analysis .....	115

4.2. Results and discussion .....	117
4.2.2. Analytical and Bio-analytical Method development and Validation.....	117
4.2.2.1. Zero order UV Spectroscopy method .....	117
4.2.2.1. LC-MS method for cell line and plasma samples.....	134
4.2.3. Compatibility and uniformity of content studies of binary systems prepared.....	144
4.2.3.1. Fourier Transform Infrared Spectroscopy (FTIR).....	144
4.2.3.2. Differential Scanning Calorimetry (DSC).....	146
4.2.4. <i>Ex-vivo</i> permeation studies .....	148
4.2.5. Cellular uptake and Transport of ACV across the Caco-2 cell monolayers.....	151
4.2.6. Pharmacokinetic studies of ACV in rabbits.....	158
4.3. Discussion.....	164
References.....	166

**Chapter V Oral uptake enhancement of Saquinavir 168-208**

5.0. Introduction.....	168
5.1. Materials and Methods.....	170
5.1.1. Materials .....	170
5.1.2. Analytical and Bio-analytical Method development and Validation.....	170
5.1.2.1. LC-MS method for estimation of SQU.....	170
5.1.3. Preparation of Physical Mixture of saquinavir and bioenhancers .....	173
5.1.3.1. Compatibility studies of binary system.....	174
5.1.4. <i>Ex-vivo</i> permeation studies (Franz diffusion cell) .....	174
5.1.5. Cellular uptake and Transport of SQU across the Caco-2 cell monolayers .....	176
5.1.6. <i>In vivo</i> pharmacokinetic studies in rabbits.....	180
5.1.6.1. Animal preparation for <i>In-vivo</i> studies .....	180
5.1.6.2. Dosing and sampling.....	180
5.1.6.3. Analysis of plasma samples .....	181
5.1.6.4. Pharmacokinetic and Statistical analysis.....	181
5.2. Results and Discussion .....	182
5.2.1. LC-MS Method for estimation of SQU .....	182
5.2.2. Compatibility and uniformity of content studies of binary systems prepared.....	185

5.2.2.1. Fourier Transform Infrared Spectroscopy (FTIR) .....	185
5.2.2.2. Differential Scanning Calorimetry (DSC) .....	187
5.2.3. Ex-vivo permeation studies.....	189
5.2.4. Cellular uptake and Transport of SQU across the Caco-2 cell monolayers .....	192
5.2.5. Pharmacokinetic studies of SQU in rabbits .....	199
5.3. Discussion .....	206
References.....	208

**Chapter VI Natural bioenhancer cruise from oral to topical 210-240**

6.0. Introduction.....	211
6.1. Plan of Work (Aim & Objectives).....	213
6.2. Materials and Methods.....	214
6.2.1. Materials .....	214
6.2.2 LC-MS Method for estimation of ACV in Cell lines and plasma samples .....	214
6.2.2. Preparation of cream .....	215
6.2.2.1. ACV content estimation.....	217
6.2.2.2. Spreadibility.....	217
6.2.3. <i>In vitro</i> skin permeation studies.....	218
6.2.4. Skin Retention Study .....	219
6.2.5. <i>Ex vivo</i> skin permeation studies.....	219
6.2.6. HaCat cell line.....	219
6.2.7. MTT Assay.....	220
6.2.8. RT-PCR.....	220
6.2.9. Draize Test.....	221
6.3. Results and Discussion.....	222
6.3.1. LC-MS Method.....	222
6.3.2. ACV content studies in cream.....	222
6.3.3. Spreadibility.....	223
6.3.4. <i>In vitro</i> skin permeation studies .....	224
6.3.5. Skin Retention Study .....	227
6.3.6. <i>Ex vivo</i> skin permeation studies .....	228

6.3.7. HaCat cell line.....	231
6.3.8. MTT Assay.....	234
6.3.9. RT-PCR.....	234
6.3.10. Draize Test.....	236
6.4. Discussion.....	237
References.....	239

**Chapter VII Discussion and Summary** **241-250**

**Publications**